Compartir
Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Aaps Advances in the Pharmaceutical Sciences Series) (en Inglés)
$ 338.410
$ 470.020
Ahorras: $ 131.610
Elige la lista en la que quieres agregar tu producto o crea una nueva lista
✓ Producto agregado correctamente a la lista de deseos.
Ir a Mis Listas
Origen: Estados Unidos
(Costos de importación incluídos en el precio)
Se enviará desde nuestra bodega entre el
Viernes 17 de Mayo y el
Martes 28 de Mayo.
Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.
Reseña del libro "Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Aaps Advances in the Pharmaceutical Sciences Series) (en Inglés)"
This book provides a comprehensive overview of the biosimilar regulatory framework, the development process and clinical aspects for development of biosimilars. The development path of a biosimilar is just as unique as a development path of a new drug, tailored by the mechanism of action, the quality of the molecule, published information on the reference product, the current competitive environment, the target market and regulatory guidance, and most importantly, the emerging totality of evidence for the proposed biosimilar during development. For the ease of readers, the book comprises of six sections as follows:Section I: Business, Health Economics and Intellectual Property Landscape for BiosimilarsSection II: Regulatory Aspects of Development and Approval for BiosimilarsSection III: Biopharmaceutical Development and Manufacturing of BiosimilarsSection IV: Analytical Similarity Considerations for BiosimilarsSection V: Clinical aspects of Biosimilar DevelopmentSection VI: Biosimilars- Global Development and Clinical ExperienceChapters have been written by one or more experts from academia, industry or regulatory agencies who have been involved with one or more aspects of biosimilar product development. The authors and editors have an expertise in commercialization and pricing of biosimilars, intellectual property considerations for biosimilars, chemistry manufacturing controls (CMC) and analytical development for biosimilars, regulatory and clinical aspects of biosimilar development. Besides the industry practitioners, the book includes several contributions from regulators across the globe.The book is edited by Hiten Gutka, Harry Yang and Shefali Kakar.
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
- 0% (0)
Todos los libros de nuestro catálogo son Originales.
El libro está escrito en Inglés.
La encuadernación de esta edición es Tapa Dura.
✓ Producto agregado correctamente al carro, Ir a Pagar.
